Tackling cisplatin resistance in ovarian cancer: what can we do?

Cancer Drug Resistance ›› 2021, Vol. 4 ›› Issue (4) :755 -7. DOI: 10.20517/cdr.2021.59

Editorial

Author information +

History +

PDF

Download citation ▾

Paola Perego. Tackling cisplatin resistance in ovarian cancer: what can we do?. Cancer Drug Resistance, 2021, 4(4): 755-7 DOI:10.20517/cdr.2021.59

登录浏览全文

4963

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Takahashi A,Chefetz I.How to win the ovarian cancer stem cell battle: destroying the roots.Cancer Drug Resist2020;3;1021-33

[2]	Meng Y,Zhang S.The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance.Cancer Drug Resist2021;4:365-81

[3]	Rinne N,Ardasheva A.Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer.Cancer Drug Resist2021;4:[Online First]

[4]	Romagnoli A,D’Agostino M,Di Marino D.Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy.Cancer Drug Resist2021;4:[Online First]